Standardization of measurement of β-amyloid((1-42)) in cerebrospinal fluid and plasma

Amyloid

Volumn 7, Issue 4, 2000, Pages 245-258

  Vanderstichele, H ^a   Van Kerschaver, E ^a   Hesse, C ^a   Davidsson, P ^a   Buyse, M A ^a   Andreasen, N ^a   Minthon, L ^a   Wallin, A ^a   Blennow, K ^a   Vanmechelen, E ^a  

^a INNOGENETICS   (Belgium)

Author keywords

Cerebrospinal fluid; ELISA; Plasma; amyloid ((1 42))

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; URINE LEVEL;

EID: 0033637408     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120009146438     Document Type: Article

References (51)

1. Consensus report of the working group on 'molecular and biochemical markers of Alzheimer's disease'
2. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's Disease
3. Alzheimer's soluble amyloid β is a normal component of human urine
4. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
5. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to the apolipoprotein E genotype
6. Improved discrimination of AD patients using β-amyloid((1-42)) and tau levels in CSF
7. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's Disease
8. Longitudinal study of cerebrospinal fluid levels of tau. Aβ1-40 and Aβ1-42(43) in Alzheimer's disease a study in Japan
9. Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease
10. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression
11. Cerebrospinal fluid β-amyloid (1-42) in Alzheimer's disease differences between early-and late-onset AD and stability during the course of disease
12. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
13. Amyloid-β peptides interact with plasma proteins and erythrocytes implications for their quantitation in plasma
14. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome
15. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's Disease
16. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
17. 4(1-42)] in CSF
18. Evidence that Aβ42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype
19. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
20. Principles of albumin and IgG analysis in neurological disorders
21. Quantitative models for prediction of toxic component concentrations in smoke gases from FTIR spectra
22. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease
23. Report of the second dementia with Lewy body international workshop diagnosis and treatment Consortium on Dementia with Lewy Bodies
24. 'Mini-Mental State' A practical method for grading the cognitive state of patients for the clinician
25. Guidelines for immunoassay data processing
26. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
27. Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls
28. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid
29. Analysis of heterogeneous βA4 peptide in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay
30. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease
31. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy
32. Assessment of amyloid β protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's Disease
33. Amyloid-β aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths
34. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma
35. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma
36. Endogenous proteins controlling amyloid β-peptide polymerization Possible implications for β-amyloid formation in the central nervous system and in peripheral tissues
37. Normal and abnormal biology of the beta-amyloid precursor protein
38. Amyloid beta-protein induces its own production in cultured degenerating cerebrovascular smooth muscle cells
39. Fate of cerebrospinal fluid-borne amyloid β-peptide rapid clearance into blood and appreciable accumulation by cerebral arteries
40. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy
41. Plateletes are the primary source of amyloid β-peptide in human blood
42. The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid beta-peptide as modeled with N-terminal decapeptide fragments
43. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion
44. Amyloid beta protein in plasma from patients with sporadic Alzheimer's Disease
45. The βAPP717 Alzheimer mutation increases the percentage of plasma amyloid-β protein ending at Aβ42(43)
46. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
47. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
48. Candidate gene for the chromosome I familial Alzheimer's disease locus
49. Plasma levels of amyloid β proteins Aβ1-40 and Aβ1-42(43) are elevated in Down's syndrome
50. Increased plasma amyloid β protein 1-42 levels in Down syndrome
51. Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease a study with quantitative magnetic resonance imaging